Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Immunic CSO outlines progress with MS therapies to mark World Brain Day
MP3•Episode home
Manage episode 430353371 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Immunic Inc chief scientific officer Hella Kohlhof discusses multiple sclerosis (MS), its development, origin, and current treatments with Proactive's Stephen Gunnion to mark World Brain Day on July 22. Kohlhof explained that MS is a chronic and unpredictable disease of the central nervous system, affecting the brain, spinal cord, and optic nerve, leading to various severe symptoms. She highlighted the recent research linking the Epstein-Barr virus to MS, emphasizing the need for continued investigation. Kohlhof discussed Immunic's lead asset, vidofludimus calcium, which is being developed for treating both relapsing and progressive MS. She explained that this drug has a dual mode of action, providing neuroprotective, anti-inflammatory, and antiviral effects. Clinical trials have shown promising results, with phase three studies underway and expected to conclude in 2026. Additionally, the phase 2 CALLIPER study in progressive MS is fully recruited, with top-line data expected in 2025. Kohlhof also shared practical advice for maintaining brain health, such as a healthy diet, regular exercise, adequate sleep, and mental engagement. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #ImmunicInc #HellaKohlhof #MultipleSclerosis #MSTreatment #NeurologicalDisorders #VidofludimusCalcium #BrainHealth #EpsteinBarrVirus #ClinicalTrials #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
607 episodes
MP3•Episode home
Manage episode 430353371 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Immunic Inc chief scientific officer Hella Kohlhof discusses multiple sclerosis (MS), its development, origin, and current treatments with Proactive's Stephen Gunnion to mark World Brain Day on July 22. Kohlhof explained that MS is a chronic and unpredictable disease of the central nervous system, affecting the brain, spinal cord, and optic nerve, leading to various severe symptoms. She highlighted the recent research linking the Epstein-Barr virus to MS, emphasizing the need for continued investigation. Kohlhof discussed Immunic's lead asset, vidofludimus calcium, which is being developed for treating both relapsing and progressive MS. She explained that this drug has a dual mode of action, providing neuroprotective, anti-inflammatory, and antiviral effects. Clinical trials have shown promising results, with phase three studies underway and expected to conclude in 2026. Additionally, the phase 2 CALLIPER study in progressive MS is fully recruited, with top-line data expected in 2025. Kohlhof also shared practical advice for maintaining brain health, such as a healthy diet, regular exercise, adequate sleep, and mental engagement. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #ImmunicInc #HellaKohlhof #MultipleSclerosis #MSTreatment #NeurologicalDisorders #VidofludimusCalcium #BrainHealth #EpsteinBarrVirus #ClinicalTrials #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
607 episodes
सभी एपिसोड
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.